RHJA
ASND icon

Rice Hall James & Associates’s Ascendis Pharma A/S ASND Stock Holding History

Rice Hall James & Associates’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.6M Buy
148,644
+258
+0.2% +$60.3K 1.93% 10
2026
Q1 		$33.9M Buy
148,386
+3,340
+2% +$749K 1.89% 9
2025
Q4 		$30.9M Sell
145,046
-2,044
-1% -$422K 1.7% 12
2025
Q3 		$29.2M Sell
147,090
-13,020
-8% -$2.43M 1.59% 14
2025
Q2 		$27.6M Sell
160,110
-686
-0.4% -$112K 1.49% 20
2025
Q1 		$25.1M Sell
160,796
-3,092
-2% -$442K 1.47% 20
2024
Q4 		$22.6M Buy
163,888
+3,274
+2% +$430K 1.24% 22
2024
Q3 		$24M Buy
160,614
+8,958
+6% +$1.21M 1.3% 22
2024
Q2 		$20.7M Sell
151,656
-10,756
-7% -$1.46M 1.24% 19
2024
Q1 		$24.6M Sell
162,412
-6,471
-4% -$924K 1.4% 18
2023
Q4 		$21.3M Sell
168,883
-904
-0.5% -$90.1K 1.23% 20
2023
Q3 		$15.9M Sell
169,787
-3,676
-2% -$344K 1.01% 27
2023
Q2 		$15.5M Buy
173,463
+18,535
+12% +$1.61M 0.88% 34
2023
Q1 		$16.6M Buy
154,928
+9,189
+6% +$1.05M 0.94% 29
2022
Q4 		$17.8M Buy
145,739
+9,294
+7% +$1.08M 1.02% 27
2022
Q3 		$14.1M Sell
136,445
-26,543
-16% -$2.52M 0.82% 37
2022
Q2 		$15.2M Buy
162,988
+28,088
+21% +$2.65M 0.73% 41
2022
Q1 		$15.8M Buy
134,900
+35,039
+35% +$4.06M 0.63% 49
2021
Q4 		$13.4M Buy
99,861
+23,095
+30% +$3.44M 0.48% 52
2021
Q3 		$12.2M Buy
76,766
+36,593
+91% +$5.01M 0.45% 63
2021
Q2 		$5.29M Hold
40,173
– – 0.19% 90
2021
Q1 		$5.18M Sell
40,173
-1,810
-4% -$275K 0.17% 109
2020
Q4 		$7M Buy
41,983
+19,696
+88% +$3.26M 0.25% 78
2020
Q3 		$3.44M Buy
+22,287
New +$3.2M 0.14% 119

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Rice Hall James & Associates's ASND Position: Q2 2026 in Review

Rice Hall James & Associates increased its Ascendis Pharma A/S (ASND) stake by 0.17% in Q2 2026, buying an estimated $60.3K and bringing the position to 148,644 shares worth $39.6M. The position accounts for 1.93% of the portfolio, ranked #10.

Rice Hall James & Associates first reported a position in ASND in Q3 2020 and has held it in 24 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Rice Hall James & Associates held 148,644 shares of Ascendis Pharma A/S worth $39.6M as of Q2 2026.
  • Rice Hall James & Associates bought 258 Ascendis Pharma A/S shares in Q2 2026, an estimated $60.3K.
  • Ascendis Pharma A/S made up 1.93% of Rice Hall James & Associates's portfolio in Q2 2026, its #10 holding.
  • Rice Hall James & Associates first reported a position in Ascendis Pharma A/S in Q3 2020 and has held it in 24 quarters since.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.